Delay for Disc as CNPV-designated bitopertin earns CRL in EPP

Written By Anna Mann

BioWorld | February 17, 2026

A piece focused on the regulatory angle, including questions about consistency and stability at the FDA after a CRL was issued for a drug that had been designated under the Commissioner’s National Priority Voucher pathway.

Read Article
Read Article
Anna Mann
Previous

FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases
Next

FDA rejects Disc’s rare disease drug despite Commissioner’s voucher